AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 2109

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

14 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now
EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Watch now
Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Watch now
NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Watch now
SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Watch now
ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF Watch now
New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD Watch now
ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Watch now
BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Watch now
KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Watch now
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation Watch now

Part 4

Highlights

1 session
3 Trials That Will Change My Practice with Dr Michelle Kittleson Watch now

About the episode

AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).

 

Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).

 

ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial investigating the use of zerlasiran (SLN360), a double-stranded small interfering ribonucleic acid (siRNA), in adults with elevated lipoprotein(a) at high risk of ASCVD events. 180 patients were enrolled in the trial and were followed-up at 36, 48 and 60 weeks. The primary outcome measure was time averaged change in lipoprotein(a) from baseline.

 

Interview Questions:
1.    What is the importance behind the ALPACAR trial?
2.    Could you tell us about the mechanism of action behind zerlasiran?
3.    What were the key findings?
4.    What further research is needed in this area, and what are the next steps?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Steven E Nissen

Steven E Nissen

Cleveland Clinic, Cleveland, US

Dr. Steven E. Nissen, an esteemed American cardiologist, researcher, and patient advocate, has left an indelible mark in the field of cardiology. Formerly the chairman of cardiovascular medicine at the renowned Cleveland Clinic in Ohio, Dr. Nissen brings a wealth of experience and expertise to his roles.

Joining the Cleveland Clinic in 1992, Dr. Nissen held key positions, including Vice-Chairman of the Department of Cardiology, Section Head of Clinical Cardiology, and Director of the Coronary Intensive Care Unit. In his most recent role, he served as the Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), overseeing multi-center clinical trials. Dr. Nissen continues to contribute periodically in the Cardiac Critical Care Unit, showcasing his ongoing commitment to patient care.

A highly accomplished academic, Dr. Nissen graduated from the Webb School of California before pursuing his undergraduate degree at the University of Michigan. He…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.